Multiple studies have suggested that one of the target genes of the YAP/TAZ axis is CD73, suggesting the idea that induction of CD73 expression may provide a selective advantage to YAP1 expressing SCLC cells under treatment (92–94). The gene discussed is YAP1; the disease is small cell lung carcinoma.